Table 1 Summary of patient population (mITT population), (a) demographic characteristics (b) screening parameters
a. | ||
|---|---|---|
Characteristic | Total | |
N = 163 | ||
Age (yr) | ||
Mean (SD) | 59.5 (9.21) | |
Sex, n (%) | ||
Male | 78 (48) | |
Ethnicity, n (%) | ||
Hispanic/Latino | 1 (<1) | |
Non-Hispanic/Latino | 162 (>99) | |
Race, n (%) | ||
White | 145 (89) | |
African American/African heritage | 16 (10) | |
African American/African heritage and White | 1 (<1) | |
American Indian or Alaskan native | 1 (<1) | |
Height (cm) | ||
Mean (SD) | 170.2 (9.20) | |
Weight (kg) | ||
Mean (SD) | 79.55 (17.539) | |
Body mass index (kg/m2) | ||
Mean (SD) | 27.36 (5.115) | |
b. | ||
Parameter | Total N = 163 | |
Pre-salbutamol | Post-salbutamol | |
% predicted FEV1 (%) | ||
n | 162 | 163 |
Mean (SD) | 47.0 (12.84) | 51.1 (10.16) |
FEV1/FVC (%) | ||
n | 162 | 163 |
Mean (SD) | 51.1 (11.65) | 52.3 (10.62) |
FEV1 (L) | ||
n | 162 | 163 |
Mean (SD) | 1.429 (0.5179) | 1.554 (0.4727) |
FVC (L) | ||
n | 162 | 163 |
Mean (SD) | 2.803 (0.7948) | 3.001 (0.8073) |
Reversibility to salbutamol (%) | ||
n | 162 | |
Mean (SD) | 11.8 (15.31) | |
Reversibility to salbutamol (mL) | ||
n | 162 | |
Mean (SD) | 124.2 (212.56) | |
Mean baseline FEV1 (L) | ||
n | 163 | |
Mean (SD) | 1.408 (0.5282) | |
Mean baseline FVC (L) | ||
n | 163 | |
Mean (SD) | 2.763 (0.7920) | |